Kristie A Blum

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi request reprint Adult Burkitt leukemia and lymphoma
    Kristie A Blum
    Division of Hematology and Oncology, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, A437 Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    Blood 104:3009-20. 2004
  2. ncbi request reprint 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma
    Kristie A Blum
    The Ohio State University, Division of Hematology and Oncology, Arthur G James Cancer Hospital, Columbus 43210 1240, USA
    Expert Opin Biol Ther 4:1323-31. 2004
  3. ncbi request reprint Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma
    Jeffrey A Jones
    Division of Hematology, The Ohio State University, Columbus, Ohio
    Am J Hematol 89:19-24. 2014
  4. doi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
    Leuk Lymphoma 49:1893-8. 2008
  5. pmc ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
    Emilia Mahoney
    Division of Hematology, Department of Internal Medicine, College of Pharmacy, The Ohio State University OSU, Columbus, OH 43210, USA
    Blood 120:1262-73. 2012
  6. pmc Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 27:6012-8. 2009
  7. pmc Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, USA
    Ther Drug Monit 30:620-7. 2008
  8. pmc Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia
    Alison R Walker
    Division of Hematology, Department of Internal Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Leuk Lymphoma 54:1996-2002. 2013
  9. pmc Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:418-23. 2010
  10. pmc Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
    Sarah E M Herman
    Integrated Biomedical Science Graduate Program, The Ohio State University Medical Center, Columbus, OH, USA
    Blood 117:6287-96. 2011

Detail Information

Publications35

  1. ncbi request reprint Adult Burkitt leukemia and lymphoma
    Kristie A Blum
    Division of Hematology and Oncology, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, A437 Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    Blood 104:3009-20. 2004
    ....
  2. ncbi request reprint 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma
    Kristie A Blum
    The Ohio State University, Division of Hematology and Oncology, Arthur G James Cancer Hospital, Columbus 43210 1240, USA
    Expert Opin Biol Ther 4:1323-31. 2004
    ..Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. 90Yttrium-ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL...
  3. ncbi request reprint Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma
    Jeffrey A Jones
    Division of Hematology, The Ohio State University, Columbus, Ohio
    Am J Hematol 89:19-24. 2014
    ..The single-agent activity of this first-generation CDKI suggests that other agents in this class merit further study in lymphoid malignancies, both alone and in combination...
  4. doi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
    Leuk Lymphoma 49:1893-8. 2008
    ..Day 100 and overall non-relapse mortality rate was 12.5% and 25%, respectively. Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates...
  5. pmc ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
    Emilia Mahoney
    Division of Hematology, Department of Internal Medicine, College of Pharmacy, The Ohio State University OSU, Columbus, OH 43210, USA
    Blood 120:1262-73. 2012
    ....
  6. pmc Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 27:6012-8. 2009
    ..Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated...
  7. pmc Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, USA
    Ther Drug Monit 30:620-7. 2008
    ..This sensitivity will enable late terminal phase concentration measurements and accurate pharmacokinetic parameter estimation in a planned clinical trial with lenalidomide and flavopiridol in patients with chronic lymphocytic leukemia...
  8. pmc Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia
    Alison R Walker
    Division of Hematology, Department of Internal Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Leuk Lymphoma 54:1996-2002. 2013
    ..Pharmacokinetic data provide insight for studies of related agents in AML. Next-generation HSP90 inhibitors are appealing for further development in this area. ..
  9. pmc Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:418-23. 2010
    ..We conducted a phase I study of flavopiridol, fludarabine, and rituximab (FFR) in patients with mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin's lymphomas (B-NHL), and CLL to determine the activity of FFR...
  10. pmc Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
    Sarah E M Herman
    Integrated Biomedical Science Graduate Program, The Ohio State University Medical Center, Columbus, OH, USA
    Blood 117:6287-96. 2011
    ..Based on these collective data, future efforts targeting BTK with the irreversible inhibitor PCI-32765 in clinical trials of CLL patients is warranted...
  11. pmc A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol
    Jia Ji
    The Comprehensive Cancer Center, College of Pharmacy, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 19:1269-80. 2013
    ..The purpose of this study was to investigate the relationships between pretreatment risk factors, drug pharmacokinetics, and TLS...
  12. doi request reprint High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Internal Medicine, Division of Hematology Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Eur J Haematol 81:425-31. 2008
    ..At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40%. The 3-yr overall survival was 52%. The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively...
  13. pmc Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
    Mitch A Phelps
    Comprehensive Cancer Center, College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH 43210, USA
    Blood 113:2637-45. 2009
    ..These composite results confirm high activity of this pharmacokinetically derived schedule in relapsed, genetically high-risk CLL. Furthermore, PK describes some, but not all, variability in response and toxicity...
  14. pmc Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma
    Lapo Alinari
    Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 43210, USA
    MAbs 1:31-40. 2009
    ....
  15. pmc Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas
    Mehdi Hamadani
    Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:547-53. 2009
    ..Given the outcomes seen here in the setting of PD, such patients should proceed with transplant only in the setting of investigational therapy...
  16. pmc Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 150:189-95. 2010
    ..In conclusion, dose-limiting myelosuppression and infectious complications prevented dose escalation of decitabine to levels associated with changes in global methylation or gene re-expression in CLL and NHL...
  17. pmc FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death
    Lapo Alinari
    Division of Hematology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 118:6893-903. 2011
    ..Significant in vivo therapeutic activity of combination treatment was also demonstrated in a preclinical, in vivo model of MCL. These findings support clinical evaluation of this combination in patients with MCL...
  18. pmc Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease
    Jennifer A Woyach
    The Ohio State University, Columbus, USA
    Br J Haematol 148:754-9. 2010
    ..2;p11.2) is a novel recurrent cytogenetic abnormality in CLL associated with early age at diagnosis and accelerated disease progression. Future efforts to identify genes disrupted by this translocation are warranted and ongoing...
  19. pmc The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
    Sarah E M Herman
    Integrated Biomedical Science Graduate Program, The Ohio State University Medical Center, Columbus, OH 43210, USA
    Blood 117:4323-7. 2011
    ....
  20. pmc Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Leuk Lymphoma 50:349-56. 2009
    ..Clofarabine exhibits evidence of single agent activity in relapsed or refractory DLBCL. However, further study with novel administration schedules that maintain this efficacy and limit toxicity is warranted...
  21. pmc The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo
    David M Lucas
    Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    PLoS ONE 5:e10941. 2010
    ..We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies...
  22. pmc Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
    John C Byrd
    Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
    N Engl J Med 369:32-42. 2013
    ..Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells...
  23. ncbi request reprint Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor
    Beth Christian
    Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    J Clin Oncol 28:e629-32. 2010
  24. pmc Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
    Rosa Lapalombella
    Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 115:2619-29. 2010
    ..This study is registered at http://clinicaltrials.gov as NCT00466895...
  25. pmc Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
    Kristie A Blum
    Division of Hematology Oncology, Ohio State University Medical Center, Columbus, OH 43210, USA
    Br J Haematol 147:507-14. 2009
    ..Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs...
  26. ncbi request reprint Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 48:1313-9. 2007
    ..Grade 3 - 4 adverse events, primarily thrombocytopenia, occurred in 15 patients. Therefore, although well tolerated, 1.3 mg/m(2) bortezomib administered biweekly has no single agent activity in relapsed/refractory classical HL...
  27. pmc Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
    Lapo Alinari
    Division of Hematology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 117:4530-41. 2011
    ..Significant in vivo therapeutic activity of combination rituximab and milatuzumab was demonstrated in a preclinical model of MCL. These data support clinical evaluation of combination milatuzumab and rituximab therapy in MCL...
  28. doi request reprint Evaluation and management of lymphoma and leukemia in pregnancy
    Jonathon B Cohen
    Department of Internal Medicine, Division of Hematology, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, Ohio, USA
    Clin Obstet Gynecol 54:556-66. 2011
    ..Many women are able to be treated successfully and deliver healthy babies...
  29. ncbi request reprint Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer 107:2817-25. 2006
    ..The objective of this study was to determine the efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) in patients with untreated, indolent non-Hodgkin lymphoma (NHL)...
  30. ncbi request reprint Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria
    Kristie A Blum
    The Ohio State University, Division of Hematology Oncology, Starling Loving Hall, Room B324, Columbus, OH 43210, USA
    J Clin Oncol 25:5624-9. 2007
    ..The widespread use of computed tomography (CT) scans has prompted many to advocate for the incorporation of this test into CLL response criteria...
  31. pmc Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma
    Jeffrey S Johnston
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 871:15-21. 2008
    ..It is the first analytical method reported to date for the quantitation of both 17AAG and its metabolite 17AG and can reliably quantitate concentrations of both compounds as low as 0.5 ng/mL...
  32. doi request reprint Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma
    Kristie A Blum
    Division of Hematology, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, OH 43210, USA
    Hematology Am Soc Hematol Educ Program 2010:93-100. 2010
    ..This review examines current data using the IPS to determine patient outcome, discuss several potential biologic prognostic markers, and summarize new therapies that are currently in clinical development in HL...
  33. ncbi request reprint Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma
    Amy L Hoerr
    School of Medicine, Siteman Cancer Center, Washington University, St Louis, MO, USA
    J Clin Oncol 22:4561-6. 2004
    ..To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL)...
  34. ncbi request reprint Antibodies for the treatment of diffuse large cell lymphoma
    Kristie A Blum
    Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA
    Semin Oncol 30:448-56. 2003
    ..These agents may be most promising when combined with either chemotherapy or with rituximab. This review will summarize the use of rituximab in the therapy of diffuse large B-cell lymphoma and briefly describe antibodies in development...
  35. ncbi request reprint Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
    Paula M Fracasso
    Alvin J Siteman Cancer Center, St Louis, Missouri, USA
    Cancer 95:2223-9. 2002
    ..We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancies...